Press Releases

Nektar's Technology Enables First-Ever PEGylation of a Small Molecule with Demonstrated Therapeutic Activity

maureen — Fri, 16 May 2008 12:48:52 -0400

Nektar's Technology Enables First-Ever PEGylation of a Small Molecule with Demonstrated Therapeutic Activity SAN CARLOS, Calif., May 16 -- Nektar Therapeutics (Nasdaq: NKTR) announced initial results Read more...

BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma

maureen — Fri, 16 May 2008 12:25:08 -0400

BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting WOBURN, Mass., May 16 /PRNewswire/ -- BioVex Inc, a Read more...

American Red Cross Vindicated in J&J Lawsuit

maureen — Fri, 16 May 2008 12:10:39 -0400

American Red Cross Vindicated in J&J Lawsuit WASHINGTON, Thursday, May 15, 2008 - A federal judge last night ruled against Johnson & Johnson (J&J) in its suit to stop the American Red Read more...

Amgen Highlights Data to Be Presented at ASCO

maureen — Fri, 16 May 2008 11:25:30 -0400

Amgen Highlights Data to Be Presented at ASCO ANKL pathway, is an example of Amgen's approach to novel drug discovery and development. The giant cell tumor data being presented at ASCO are from a Read more...

Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by M

maureen — Fri, 16 May 2008 10:50:41 -0400

Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting Thursday May 15, 4:15 pm Read more...

Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study

maureen — Fri, 16 May 2008 10:44:52 -0400

Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study - Trial Results Confirm Efficacy for Population Most Affected by Disease - WAYNE, N.J. and EMERYVILLE, Read more...

Invitrogen Corporation Launches Cell Therapy Business Unit

maureen — Fri, 16 May 2008 10:34:28 -0400

Invitrogen Corporation Launches Cell Therapy Business Unit 5/16/2008 CARLSBAD, Calif. -- Invitrogen Corporation, a provider of essential life science technologies for research, production and Read more...

PharmacopeiaShares Rise On Blood Pressure Study; Investigational Therapy PS433540 Achieves Statistically Significant Reductions

maureen — Fri, 16 May 2008 10:18:06 -0400

PharmacopeiaShares Rise On Blood Pressure Study; Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients Single Molecule with Dual Read more...

Presented At The American Society Of Clinical Oncology Meeting

maureen — Fri, 16 May 2008 09:56:18 -0400

Presented At The American Society Of Clinical Oncology Meeting South San Francisco, Calif. -- May 15, 2008 -- Genentech, Inc. (NYSE:DNA) today announced results from studies of several Read more...

Antisoma plc (UK) - Antisoma to Acquire Boston-Based Xanthus Pharmaceuticals

maureen — Fri, 16 May 2008 08:49:15 -0400

Antisoma plc (UK) - Antisoma to Acquire Boston-Based Xanthus Pharmaceuticals LONDON, and BOSTON, 16 May 2008 - Cancer-focused biotechnology company Antisoma today announces that it has entered into Read more...

Dynavax TOLAMBA Chamber Study Misses Primary Endpoint; Company Updates 2008 Financial Outlook

maureen — Fri, 16 May 2008 07:56:07 -0400

Dynavax TOLAMBA Chamber Study Misses Primary Endpoint; Company Updates 2008 Financial Outlook BERKELEY, Calif.--(BUSINESS WIRE)--May 16, 2008 - Dynavax Technologies Corporation (Nasdaq:DVAX) today Read more...

ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study

Fri, 16 May 2008 07:20:32 -0400

SAN DIEGO, May 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that, in a registrational bioequivalence clinical study, ANX-530 demonstrated a statistically Read more...

Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study

Fri, 16 May 2008 04:19:57 -0400

WAYNE, N.J. and EMERYVILLE, Calif., May 16 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that Nexavar(R) (sorafenib) Read more...

Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting

Fri, 16 May 2008 04:19:44 -0400

WAYNE, N.J. and EMERYVILLE, Calif., May 16 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced more than 40 data Read more...

Arpida Announces FDA Acceptance of the Iclaprim New Drug Application

Fri, 16 May 2008 04:19:38 -0400

REINACH, Switzerland, May 16 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) Read more...